| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
121,380,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0 - $0 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Guardant Health is a precision oncology company focused on helping conquer cancer globally through use of its proprietary blood-based tests, data sets and analytics. Co. is engaged in the clinical liquid biopsy market with its Guardant360 and GuardantOMNI tests. Co.'s Guardant360 test is a molecular diagnostic test measuring a number of cancer-related genes and its GuardantOMNI test has a 500-gene panel, both of which analyze circulating tumor DNA in blood. In addition, Co. is developing tests from its LUNAR-1 program for minimal residual disease and recurrence detection in cancer survivors, and its LUNAR-2 program for early detection of cancer.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
2,187 |
2,187 |
98,220 |
| Total Buy Value |
$0 |
$38,963 |
$38,963 |
$2,585,297 |
| Total People Bought |
0 |
1 |
1 |
2 |
| Total Buy Transactions |
0 |
1 |
1 |
4 |
| Total Shares Sold |
100 |
200 |
8,325 |
31,716 |
| Total Sell Value |
$2,787 |
$4,692 |
$233,035 |
$1,293,892 |
| Total People Sold |
1 |
1 |
2 |
3 |
| Total Sell Transactions |
1 |
2 |
6 |
12 |
| End Date |
2024-03-24 |
2023-12-22 |
2023-06-23 |
2022-06-23 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Talasaz Amirali |
Chairman, President and COO |
• • – |
2020-04-20 |
4 |
AS |
$72.25 |
$198,028 |
D/D |
(2,729) |
71,060 |
|
- |
|
| Talasaz Amirali |
Chairman, President and COO |
• • – |
2020-04-20 |
4 |
OE |
$4.18 |
$11,407 |
D/D |
2,729 |
73,789 |
|
- |
|
| Talasaz Amirali |
Chairman, President and COO |
• • – |
2020-04-17 |
4 |
AS |
$72.57 |
$2,125,047 |
I/I |
(29,230) |
3,150,241 |
|
- |
|
| Talasaz Amirali |
Chairman, President and COO |
• • – |
2020-04-17 |
4 |
AS |
$72.57 |
$564,959 |
D/D |
(7,771) |
71,060 |
|
- |
|
| Talasaz Amirali |
Chairman, President and COO |
• • – |
2020-04-17 |
4 |
OE |
$4.18 |
$32,483 |
D/D |
7,771 |
78,831 |
|
- |
|
| Eltoukhy Helmy |
Chief Executive Officer |
• • – |
2020-04-17 |
4 |
AS |
$70.21 |
$1,116,739 |
D/D |
(15,904) |
3,174,980 |
|
- |
|
| Eltoukhy Helmy |
Chief Executive Officer |
• • – |
2020-04-16 |
4 |
AS |
$70.01 |
$14,001 |
D/D |
(200) |
3,190,884 |
|
- |
|
| Eltoukhy Helmy |
Chief Executive Officer |
• • – |
2020-04-14 |
4 |
AS |
$70.06 |
$189,241 |
D/D |
(2,701) |
3,191,084 |
|
- |
|
| Clark Ian T |
Director |
– • – |
2020-04-14 |
4 |
AS |
$70.00 |
$188,230 |
D/D |
(2,689) |
1,302 |
|
- |
|
| Clark Ian T |
Director |
– • – |
2020-04-14 |
4 |
OE |
$4.18 |
$11,240 |
D/D |
2,689 |
3,991 |
|
- |
|
| Meresman Stanley J |
Director |
– • – |
2020-04-13 |
4 |
AS |
$66.62 |
$632,890 |
D/D |
(9,500) |
1,302 |
|
- |
|
| Meresman Stanley J |
Director |
– • – |
2020-04-13 |
4 |
OE |
$5.94 |
$56,430 |
D/D |
9,500 |
10,802 |
|
- |
|
| Talasaz Amirali |
Chairman, President and COO |
• • – |
2020-04-02 |
4 |
AS |
$65.63 |
$1,323,895 |
I/I |
(19,750) |
3,179,471 |
|
- |
|
| Talasaz Amirali |
Chairman, President and COO |
• • – |
2020-04-02 |
4 |
AS |
$65.63 |
$351,922 |
D/D |
(5,250) |
71,060 |
|
- |
|
| Talasaz Amirali |
Chairman, President and COO |
• • – |
2020-04-02 |
4 |
OE |
$4.18 |
$21,945 |
D/D |
5,250 |
76,310 |
|
- |
|
| Eltoukhy Helmy |
Chief Executive Officer |
• • – |
2020-03-31 |
4 |
AS |
$70.61 |
$7,292,414 |
D/D |
(103,103) |
3,193,785 |
|
- |
|
| Eltoukhy Helmy |
Chief Executive Officer |
• • – |
2020-03-30 |
4 |
AS |
$67.00 |
$12,436,693 |
D/D |
(178,093) |
3,296,888 |
|
- |
|
| Clark Ian T |
Director |
– • – |
2020-03-25 |
4 |
AS |
$70.00 |
$37,660 |
D/D |
(538) |
1,302 |
|
- |
|
| Clark Ian T |
Director |
– • – |
2020-03-25 |
4 |
OE |
$4.18 |
$2,249 |
D/D |
538 |
1,840 |
|
- |
|
| Bertocci Derek A |
Chief Financial Officer |
• – – |
2020-03-24 |
4 |
AS |
$61.55 |
$7,422 |
D/D |
(114) |
84,962 |
|
- |
|
| Bertocci Derek A |
Chief Financial Officer |
• – – |
2020-03-24 |
4 |
OE |
$8.80 |
$1,003 |
D/D |
114 |
85,076 |
|
- |
|
| Bertocci Derek A |
Chief Financial Officer |
• – – |
2020-03-23 |
4 |
AS |
$60.32 |
$1,158,433 |
D/D |
(19,100) |
84,962 |
|
- |
|
| Bertocci Derek A |
Chief Financial Officer |
• – – |
2020-03-23 |
4 |
OE |
$3.63 |
$88,612 |
D/D |
19,100 |
104,062 |
|
- |
|
| Kaul Samir |
Director |
– • – |
2020-03-04 |
4 |
S |
$81.49 |
$2,059,540 |
I/I |
(25,000) |
87,943 |
|
- |
|
| Clark Ian T |
Director |
– • – |
2020-03-03 |
4 |
AS |
$78.33 |
$210,708 |
D/D |
(2,690) |
1,302 |
|
- |
|
707 Records found
|
|
Page 20 of 29 |
|
|
